Residual DNA Testing
Residual DNA Testing Supporting Biologics and Cell and Gene Therapy Development
Residual DNA testing plays a critical step in biologics and cell and gene therapy product quality and safety assessment, process validation, evaluating batch to batch variation and GMP lot release.
DNA contamination in biopharmaceuticals
Impurity testing is crucial during the manufacturing process of biopharmaceutical products, in particular those produced in bacterial or eukaryotic cell lines. As part of quality control requirements, biological products manufactured in cell lines must demonstrate that the levels of host cell DNA do not exceed regulatory guidelines (e.g. WHO and FDA guidelines for residual DNA) while also demonstrating effective purification during manufacturing.
Our residual DNA analysis allows compliance with the ICH Q6B Guidelines for a range of GLP/GCP/GCMP compliant methods which are highly accurate, target-specific and sensitive (< 1 copy per µL of template). Real-time qPCR and digital droplet PCR (ddPCR) techniques offer robust quantification to support process validation, monitor batch to batch variation and support of GMP lot release, helping to ensure that products produced from a range of common host cell lines (HEK293, E.coli and CHO cells) meet specification limits for these process impurities. Our assays have been designed and developed in-house and we therefore have the expertise to develop residual DNA assays for any other cell type you may require.
Residual DNA testing methods
The gold standard for residual DNA analysis is based on relative quantification of sample using real-time qPCR, however, digital droplet PCR (ddPCR) provides a number of key advantages over the traditional method. The partitioning nature of ddPCR generates up to 20,000 oil encapsulated droplets where effectively 20,000 individual reactions are performed. The droplet technology offers greater tolerance to PCR inhibitors, improved assay sensitivity and reduced variability, giving a more precise and absolute quantification of the DNA impurity in the biologic therapeutic product without using a standard curve. In addition, the technique can also be used to confirm discoveries made through Next Generation Sequencing (NGS) results.
Intertek’s residual DNA analysis expertise
We deploy both qPCR and ddPCR approaches to residual DNA analysis to support your biologics or cell and gene therapy development programs. Our experienced scientists lead your projects which are tailored to meet your specific needs and function as study directors or project managers.
We are adept at method development and validation and routinely work to ICH GMP/GCP/GLP guidelines but can also provide non-regulatory research and development services. With a deep understanding of the latest regulatory developments, we can help you to meet the requirements for authorisation in all global regions, providing regulatory compliant data every time. Our experts ensure the data you need meets the requirements of Good Manufacturing Practice (GMP), the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and OECD GLP regulatory standards.
With efficient communication and project implementation, underpinned by professional reporting and an independent quality assurance function, we offer Total Quality Assurance to help you meet specifications and support your regulatory submissions (clinical trial application (CTA), investigational new drug application (IND), marketing authorisation application (MAA) or new drug application (NDA) / biologics license application (BLA)).
BROCHURE: mRNA Vaccine and Therapeutic Products Analytical Development Services NEW
BROCHURE: Cell and Gene Therapy Analytical Development Services
WEBINAR: Comparison of Analytical Methods for Residual DNA Quantification
CASE STUDY: CMC Considerations for mRNA Based Therapies
CASE STUDY: Determining Viral Vector Purity with CryoTEM Techniques
CASE STUDY: Addressing Key Attributes of Viral Vectors
ARTICLE: Physicochemical Properties of Liposomal Advanced Drug Delivery Technologies
REPORT: Cell and Gene Therapy - Analytics, Manufacturing and Supply Chain
COVID-19 VACCINE OR THERAPEUTIC TESTING & DEVELOPMENT SUPPORT
IMMEDIATE QUESTION? Ask our experts now
FACTSHEET: COVID-19 Vaccine or Therapeutic Testing & Development Outsourcing
ARTICLE: Repurposing Vaccines for Intranasal Development
WEBINAR: Quality Control Strategy for Vaccine Development
WEBINAR: Repurposing Drugs for Inhaled Delivery
eBOOK: Contingency Outsourcing Solutions
NEW! Discover our Audit Live Tool for direct access to our scheduled audits
EVENT: 2nd Annual Inhaled and Nasal Biologics/DNA Forum - REGISTRATION IS LIVE
VIDEO:EXTRACTABLES/LEACHABLES LAB TOUR - Request access
WORKSHOP: How to Build an Inhaler (RDD 2023)
PRESENTATION:E&L Strategies (3rd Annual Extractables & Leachables Conference)
TALK: Medical Device Extractables & Leachables Studies
TALK: ID and sensitivity issues during E&L studies
ARTICLE: Glycosylation Analytical Approaches for Antibody Therapeutics
APP NOTE: Rapid Determination of Low/Trace Level Benzene in Pharmaceutical Excipients and Finished Products
ARTICLE: Importance of Aligning a Pharma Audit Scope with the Correct Standard
TALK: mRNA Analytics: Capping Efficiency, Sequencing, Poly-A Tail, dsRNA